Patients
idiopathic or drug-induced pneumonitis, pneumonitis, emphysema, pain
PNEUMONITIS, PULMONARY FIBROSIS, INTERSTITIAL PNEUMONIA, BONE LESIONS, SOLID TUMORS, CENTRAL NERVOUS SYSTEM METASTASES, EMPHYSEMA, HEPATIC METASTASIS, ONCOLOGY
Patients aged ≥ 20 years diagnosed with advanced solid tumors and resistant to standard therapy or no standard therapy and met the selection criteria were included in the study. The main inclusion criteria were:1) patients with an Eastern Clinical Oncology Group performance status of 0–1; 2) preserved organ and bone marrow functions (absolute neutrophil count ≥ 1500/μL, platelet count ≥ 100,000/μL, hemoglobin ≥ 9 g/dL; serum creatinine ≤ 1.5 × the upper limit of the normal range or estimated creatinine clearance ≥ 50 mL/min; total serum bilirubin ≤ 1.5 × the upper limit of the normal range, AST and ALT ≤ 3.0 × the upper limit of the normal range (≤ 5.0 × the upper limit of the normal range in the case of hepatic metastasis). The main exclusion criteria were:1) active, uncontrolled, or symptomatic central nervous system metastases; 2) interstitial pneumonia, pulmonary fibrosis, or severe emphysema; 3) a history of radiation pneumonitis or idiopathic or drug-induced pneumonitis; 4) major surgery performed or scheduled, or receiving immunotherapy, antibody therapy, or other biologic or radiation therapy within 4 weeks of enrollment.; 5) receiving cytotoxic chemotherapy or hormone therapy within 14 days of enrollment and palliative radiation therapy for pain management of bone lesions within 7 days of enrollment.